A pilot study of NY-ESO-1b peptide plus CpG 7909 and montanide ISA-51 in patients with cancer expressing NY-ESO-1 or LAGE-1.
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2009
At a glance
- Drugs Cancer vaccine NY-ESO-1 (Primary) ; Agatolimod; Montanide ISA-51
- Indications Cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 24 Mar 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 28 Aug 2006 Status change